These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Competitive collaboration in the pharmaceutical and biotechnology industry. Bingham A; Ekins S Drug Discov Today; 2009 Dec; 14(23-24):1079-81. PubMed ID: 19835979 [No Abstract] [Full Text] [Related]
43. BIO 2006 Annual International Convention. The current state of the global biotechnology industry. Zarkowska T IDrugs; 2006 Jun; 9(6):381-2. PubMed ID: 16752301 [No Abstract] [Full Text] [Related]
44. Physician executives as opinion leaders in biotechnology and pharmaceuticals. Tan RS Physician Exec; 2003; 29(3):26-8. PubMed ID: 12774722 [No Abstract] [Full Text] [Related]
45. Specifications from a biotechnology industry perspective. Garnick RL Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680 [TBL] [Abstract][Full Text] [Related]
46. Aligning career ladders and the company vision. Troia JA Nat Biotechnol; 2006 Mar; 24(3):363-4. PubMed ID: 16525411 [No Abstract] [Full Text] [Related]
47. Biotechnology. Another major deal. Gershon D Nature; 1991 Sep; 353(6342):291. PubMed ID: 1922330 [No Abstract] [Full Text] [Related]
48. Bioentrepreneurship 2002: at home in your lab. Eisenhardt PE Anal Bioanal Chem; 2002 Jan; 372(1):9-11. PubMed ID: 11939216 [No Abstract] [Full Text] [Related]
50. Biotechnology company's shares dive 67% after drug failure. Dobson R BMJ; 2000 Oct; 321(7268):1039. PubMed ID: 11053161 [No Abstract] [Full Text] [Related]
51. [Assessment and empirical analysis of the competitiveness of bioindustry in various regions of China]. Yin Z; Bai J; Lin X Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2216-2225. PubMed ID: 33169585 [TBL] [Abstract][Full Text] [Related]
52. Sponsor relationships, analyte stability in ligand-binding assays and critical reagent management: a bioanalytical CRO perspective. Lefor Bradford J Bioanalysis; 2015; 7(11):1337-46. PubMed ID: 26110706 [TBL] [Abstract][Full Text] [Related]
53. Biotechnology at Yale. Shiao S Yale J Biol Med; 2001; 74(3):197-9. PubMed ID: 11501716 [No Abstract] [Full Text] [Related]
54. Biotechnology--the enormous cost of success. Levy R N Engl J Med; 1991 Oct; 325(16):1177-8. PubMed ID: 1891031 [No Abstract] [Full Text] [Related]
55. Biotechnology. Mixed reactions to merger. Gershon D Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541 [No Abstract] [Full Text] [Related]
56. The challenges of process analytical technologies in chemical development. Grosso JA; Landau RN; Confalone PN Curr Opin Drug Discov Devel; 2005 Nov; 8(6):682-3. PubMed ID: 16312144 [No Abstract] [Full Text] [Related]
57. Data driven CRO benchmarking for biomarker analysis. Dolman A; Yu X; Gusev AI Bioanalysis; 2020 Aug; 12(16):1117-1127. PubMed ID: 32885989 [TBL] [Abstract][Full Text] [Related]
58. 2014-the biotech bull rages on. Yang W Nat Biotechnol; 2015 Feb; 33(2):123. PubMed ID: 25658268 [No Abstract] [Full Text] [Related]
59. Drug development. Orphan drug windfalls? Gershon D Nature; 1992 Jan; 355(6359):381. PubMed ID: 1734267 [No Abstract] [Full Text] [Related]